Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Sezary Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Leukemia 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × Bexarotene × Clear all
NCT00055991 2013-02-05

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

Baylor Breast Care Center

Phase 1 Completed
87 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡